Last reviewed · How we verify
Prednisolone acetate eye drops
Prednisolone acetate is a corticosteroid that suppresses local inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production.
Prednisolone acetate is a corticosteroid that suppresses local inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene production. Used for Inflammation and pain following ocular surgery, Allergic conjunctivitis, Anterior uveitis.
At a glance
| Generic name | Prednisolone acetate eye drops |
|---|---|
| Sponsor | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a glucocorticoid, prednisolone acetate binds to cytoplasmic glucocorticoid receptors, translocates to the nucleus, and modulates gene expression to decrease inflammatory mediator synthesis and immune cell infiltration. When applied topically as eye drops, it achieves high local concentration in ocular tissues while minimizing systemic absorption, making it effective for treating anterior segment inflammation.
Approved indications
- Inflammation and pain following ocular surgery
- Allergic conjunctivitis
- Anterior uveitis
- Corneal injury
- Steroid-responsive inflammatory conditions of the anterior segment
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Local irritation or stinging
- Delayed corneal wound healing
- Secondary ocular infection
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration (PHASE1, PHASE2)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: